Economic cost for implementation of the U.S. Food and Drug Administration's Code of Federal Regulations Title 21, Part 1271 in an egg donor program

Baker, Valerie L.; Gvakharia, M.; Rone, Heather M.; Manalad, J.R.; Adamson, G. David

doi:10.1016/j.fertnstert.2007.06.100

Cited by 4 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cost of oocyte donation in the USA is quite high for many reasons including the need to comply with strict FDA screening [28], routine genetic screening [29], compensation to donors, agency fees, and the medical costs for procedures that are charged by individual IVF programs. Given the high cost of oocyte donation, some programs will split oocytes between two recipient couples.…”

Section: Other Issues That Must Be Consideredmentioning

confidence: 99%

Mild ovarian stimulation for in vitro fertilization: one perspective from the USA

Baker

2013

J Assist Reprod Genet

Self Cite

View full text Add to dashboard Cite

Purpose To provide a perspective regarding mild ovarian stimulation, taking into account particular issues relevant in the United States Methods Literature review and editorial commentary Results Mild ovarian stimulation for IVF has some proven and some theoretical advantages over conventional stimulation, such as lower risk of ovarian hyperstimulation syndrome and lower cost per fresh IVF cycle. However, cumulative live birth rate, including transfers from fresh and frozen embryos, is likely to be lower with mild stimulation. The cost-effectiveness of mild stimulation IVF in the United States has not been established. Conclusions Mild ovarian stimulation is an appropriate option to consider for certain patient groups or based on patient preference. However, significant potential disadvantages limit its widespread acceptability for patients in the United States at this time.

show abstract

Section: Other Issues That Must Be Consideredmentioning

confidence: 99%

Mild ovarian stimulation for in vitro fertilization: one perspective from the USA

Baker

2013

J Assist Reprod Genet

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the United States, Food and Drug Administration regulations have added to the cost. 49 It is somewhat difficult to define the appropriate and cost-effective genetic evaluation of the oocyte donor, particularly given the proliferation of available genetic tests. 50 Oocyte donation is not ethically or socially acceptable for all couples, and alternatives to oocyte donation would likely be welcomed by women with POI.…”

Section: Challenges With Oocyte Donationmentioning

confidence: 99%

Life Plans and Family-Building Options for Women with Primary Ovarian Insufficiency

Baker

2011

Semin Reprod Med

View full text Add to dashboard Cite

Primary ovarian insufficiency (POI) compromises a woman's chance of conceiving with her own oocytes. Although biomarkers such as serum follicle-stimulating hormone, serum antimüllerian hormone, and assessment of antral follicle count by transvaginal ultrasound can give some general idea about ovarian activity and perhaps fertility potential, no marker will definitively predict if and when childbearing will be possible for women with POI. No medical therapy has yet been definitively proven to improve ovarian function and fertility for women with overt POI. Fertility preservation, with cryopreservation of ovarian tissue, oocytes, or embryos, can be considered for some women with POI if oocytes are retrievable and current childbearing is not desired, with the caveat that data regarding long-term safety and efficacy are not available for women with POI. Options with a high chance of success are oocyte donation, embryo donation, and adoption. Child-free living may be a reasonable choice for some women. It is beneficial for women with POI to hear all life-plan and family-building options presented in a balanced manner.

show abstract

Regulation and Legal Concerns in IVF

Adamson

2012

In Vitro Fertilization

View full text Add to dashboard Cite

Economic cost for implementation of the U.S. Food and Drug Administration's Code of Federal Regulations Title 21, Part 1271 in an egg donor program

Cited by 4 publications

References 3 publications

Mild ovarian stimulation for in vitro fertilization: one perspective from the USA

Mild ovarian stimulation for in vitro fertilization: one perspective from the USA

Life Plans and Family-Building Options for Women with Primary Ovarian Insufficiency

Regulation and Legal Concerns in IVF

Contact Info

Product

Resources

About